Business Wire - The global leader in news distribution
Updated: 30 sec ago
Publication of Clinical Data Demonstrating Low Immunogenicity and Excellent Efficacy of Nuwiq® in Previously Untreated Patients
LACHEN, Switzerland--(BUSINESS WIRE)--Publication of interim clinical data demonstrating low immunogenicity and excellent efficacy of Nuwiq® in PUPs with severe haemophilia A.
WARREN, N.J.--(BUSINESS WIRE)--Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors. Celularity has been created through
ATHOLVILLE, New Brunswick--(BUSINESS WIRE)--International Herbs and Medical Marijuana Ltd is pleased to confirm that Health Canada has issued a License to Cultivate for its Atholville facility. Combined with an earlier License for its Delta, BC facility, the Company now has a Coast to Coast presence. "This is a significant milestone and the result of hard work on the part of our staff and contractors," stated CEO Kevin Coft. "This would not have been possible without the assistance of our MP, R
DESSAU, Germany & CAMBRIDGE, Ontario--(BUSINESS WIRE)--IDT Biologika, a world leader in vaccines, and Gallant Custom Laboratories, an IDT Biologika company serving the animal health industry, have purchased a new facility in Canada that will significantly enhance the company’s vaccine development and manufacturing capabilities. The companies plan to build out the facility as a technological beacon for veterinary medicine and livestock health in the region. Gallant currently produces autogenous
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, has scheduled a conference call to be held Tuesday August 22, 2017 at 9:00 a.m. EDT, to discuss the third quarter ended June 30, 2017, financial results. The Company intends to release its Q3 financial results on Monday August 21, 2017. The call will be held Tuesday, August 22, 2017 at 9:00 a.m. EDT. To participate in the live call please dial: Loc
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be featuring IV Clear while exhibiting for the first time at the 41st Association of Pediatric Hematology/Oncology Nurses annual conference and exhibit at the Palm Springs Convention Center, from August 17-19, 2017. Along with IV Clear, Covalon will feature its proprietary line of infection management dressings for both
Turnstone Biologics Strengthens Leadership Team with Appointment of Kris Elverum as Chief Business Officer and Dr. José Manuel Otero as Vice President, Manufacturing and CMC
OTTAWA, Ontario & NEW YORK--(BUSINESS WIRE)--Turnstone announced the appointment of Kris Elverum as chief business officer and José Manuel (Manny) Otero, Ph.D., as VP of manufacturing and CMC.
VANCOUVER, British Columbia & SAN RAFAEL, Calif.--(BUSINESS WIRE)--RepliCel joined MedCision’s ThawSTAR® Early Adopter Program, which helps companies and investigators de-risk thawing of cell therapies.
Cambridge Epigenetix and NuGEN Technologies Sign Partnership Agreement to Combine Leading Technologies in Epigenetics Research
CAMBRIDGE, England--(BUSINESS WIRE)--#TrueMethyl--Cambridge Epigenetix and NuGEN, leaders in innovative epigenetic technologies, announced that they have entered into a partnership agreement.
DUBAI, United Arab Emirates--(BUSINESS WIRE)--Masimo announced that the Dubai Health Authority is augmenting its current inventory of Masimo equipment and technology with Masimo Patient SafetyNet.
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX: ASP) today reported its financial results for the three and six-month period ended June 30, 2017. Unless otherwise noted, all amounts are in U.S. dollars. In addition to the licensing transaction with Hyundai Pharm Co., which closed in Q4 2016, the company has entered into two new Natesto® commercial partnerships with Therios Health Care (“Therios”) for Saudi Arabia, the United Arab Emirates and Egypt, and with medac Gesellschaf
CHARLESTON, S.C.--(BUSINESS WIRE)--Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies, today reported financial and operating results for the second quarter ended June 30, 2017. Commenting on recent key developments, Michael V. Ward, Chief Executive Officer of the Company, stated, “On June 30, 2017, we reported that we re-submitted an NDA for Macrilen™, which was ahead o
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Reports Second Quarter 2017 Financial Results, and Provides Operational Highlights
FDA Allows WIN Consortium to Proceed with Targeted Tri-Therapy Clinical Trial in First Line Treatment of Metastatic Non Small Cell Lung Cancer
VILLEJUIF, France--(BUSINESS WIRE)--FDA allows WIN Consortium to proceed with targeted tri-therapy clinical trial in first line treatment of metastatic Non Small Cell Lung Cancer.
CHARLESTON, S.C.--(BUSINESS WIRE)--#AEZS--Aeterna Zentaris Engages Advisors and Provides Update to Shareholders.
SEATTLE--(BUSINESS WIRE)--Juno Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks”) (NYSE: ZYME; TSX: ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today reported financial results for the second quarter ended June 30, 2017. “During the second quarter, in addition to the completion of our initial public offering, we made significant progress o
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (www.generex.com) (OTCPink:GNBT) today provided the following summary of the Ii-Key Hybrid Vaccine Platform under development by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). This summary has been prepared by Dr. Jason B. Terrell, MD, the Company’s Chief Medical and Scientific Officer, as a follow-up to last week’s announcement by Generex of a clinical trial collaboration agreement between Antigen E
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo announced the findings of a recent study in which researchers evaluated the performance of Masimo SpHb® in trauma patients with low hemoglobin.
CHARLESTON, S.C.--(BUSINESS WIRE)--Aeterna Zentaris to Announce Second Quarter 2017 Financial and Operating Results on August 10, 2017